Eli Lilly and Company
LLY
$738.21
-$50.88-6.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.53B | 11.44B | 11.30B | 8.77B | 9.35B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.53B | 11.44B | 11.30B | 8.77B | 9.35B |
| Cost of Revenue | 2.40B | 2.17B | 2.17B | 1.67B | 1.79B |
| Gross Profit | 11.13B | 9.27B | 9.13B | 7.09B | 7.57B |
| SG&A Expenses | 2.31B | 1.98B | 2.00B | 1.84B | 1.81B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.74B | 6.89B | 6.88B | 6.03B | 6.16B |
| Operating Income | 5.80B | 4.55B | 4.42B | 2.74B | 3.19B |
| Income Before Tax | 5.04B | 1.59B | 3.52B | 2.54B | 2.51B |
| Income Tax Expenses | 628.90M | 618.10M | 550.20M | 293.20M | 319.10M |
| Earnings from Continuing Operations | 4.41B | 970.30M | 2.97B | 2.24B | 2.19B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.41B | 970.30M | 2.97B | 2.24B | 2.19B |
| EBIT | 5.80B | 4.55B | 4.42B | 2.74B | 3.19B |
| EBITDA | 6.28B | 5.02B | 4.83B | 3.14B | 3.58B |
| EPS Basic | 4.88 | 1.08 | 3.29 | 2.49 | 2.42 |
| Normalized Basic EPS | 3.87 | 3.04 | 2.96 | 1.83 | 2.13 |
| EPS Diluted | 4.88 | 1.07 | 3.28 | 2.48 | 2.42 |
| Normalized Diluted EPS | 3.87 | 3.03 | 2.95 | 1.82 | 2.13 |
| Average Basic Shares Outstanding | 903.16M | 901.00M | 900.90M | 900.80M | 903.98M |
| Average Diluted Shares Outstanding | 903.16M | 905.00M | 904.20M | 903.80M | 903.98M |
| Dividend Per Share | 1.30 | 1.30 | 1.30 | 1.30 | 1.13 |
| Payout Ratio | 26.49% | 120.63% | 39.51% | 52.13% | 46.49% |
